Cronos Group stock gets a higher CAD 5.50 analyst target

Published on 10/07/2026 at 03:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cronos Group stock carries a CAD 5.50 analyst target after its September 24 Investor Day. Q2 revenue reached USD 53.0 million, up 58 percent year over year.

CRON, CA22717L1013, Illustration mit AI erstellt.

Cronos Group (ISIN CA22717L1013) was last at USD 3.29 on Nasdaq on October 6, 2026, with a daily gain of 1.08 percent. After the company showcased its production platform on September 24, an analyst raised the 12-month target from CAD 5.25 to CAD 5.50.

Analyst lifts target after Investor Day

According to Investing.com on September 28, 2026, the analyst retained a Buy rating and increased the target from CAD 5.25 to CAD 5.50 after the Investor Day and site tour. The report highlighted the fully utilized GrowCo facility, the genetics platform and the company's branded cannabis portfolio.

The operational figures give that target a measurable basis. GrowCo was producing 13.6 metric tons of cannabis per month, while the company ranked first in Canadian vapes and edibles during the second quarter, according to management's Q2 presentation and call commentary.

Q2 revenue reaches USD 53.0 million

Cronos Group reported Q2 2026 revenue of USD 53.0 million on August 6, 2026, an increase of 58 percent from Q2 2025. Gross profit reached USD 28.5 million, up 96 percent year over year, producing a gross margin of 54 percent.

Adjusted EBITDA reached USD 13.1 million in Q2 2026, compared with USD 1.7 million a year earlier. Operating expenses were USD 21.0 million, up USD 1.2 million year over year, so the margin improvement came with a higher cost base as well as stronger sales.

Dutch deal deadline reaches October 15

Execution remains tied to CanAdelaar in the Netherlands. The Globe and Mail reported that the September 8, 2026 amendment moved the long-stop date from September 9 to October 15, 2026. The transaction still depends on regulatory clearance and other closing conditions.

The balance sheet gives Cronos room to fund expansion and repurchases. Management reported USD 827 million in cash, short-term investments and non-current interest-bearing deposits at the end of Q2 2026, alongside USD 24 million of positive operating cash flow during the quarter.

Nasdaq stock remains below yearly high

Cronos Group stock was last at USD 3.29 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a 52-week range of USD 2.28 to USD 3.61. The quote stood 8.9 percent below the yearly high, while market capitalization was USD 1.2 billion.